A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

Q2W Inclusion Criteria:

- Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

- Performance Status of 0, 1, or 2

- Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

- OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
mullerian tumors, unresolved bowel obstruction

- Brain metastases requiring steroids

- Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
study treatment start

- Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
or for whom no standard therapy is available

- Performance Status of 0 or 1

- Adequate bone marrow, kidney, and liver function

- Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
non small cell lung cancer patients

Q3W Exclusion Criteria:

- OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
unresolved bowel obstruction

- Brain metastases requiring steroids

- Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
study treatment start

- Active and clinically significant bacterial, fungal, or viral infection